Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774653 | 0.78 | TSHR (0.52) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL24769797 | 0.78 | SLC1A3 (0.43) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| Bromide SCHEMBL29142495 | 0.78 | RCE1 (0.49) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| Bromide SCHEMBL29032034 | 0.76 | CA1 (0.50) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL18697922 | 0.75 | RCE1 (0.43) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL18133061 | 0.74 | RCE1 (0.49) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL620072 | 0.74 | TSHR (0.48) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL23735671 | 0.74 | SLC1A1 (0.56) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL51132 | 0.74 | RCE1 (0.49) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A | |
| SCHEMBL29172647 | 0.74 | CA1 (0.48) | ALDH1A1SLC1A3SLC1A2SLC1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539251-A4 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | GLYCOMIMETICS INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1685145-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GlycoMimetics, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1575619-A1 | OLIGOSACCHARIDES AND CONJUGATES THEREOF FOR THE TREATEMENT OF PSEUDOMONAS BACTERIA INFECTION | Glycomimetics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | GLYCOMIMETICS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005054264-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1539251-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | Glycomimetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040219158-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria | GLYCOMIMETICS, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004058304-A1 | OLIGOSACCHARIDES AND CONJUGATES THEREOF FOR THE TREATEMENT OF PSEUDOMONAS BACTERIA INFECTION | GLYCOMIMETICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040096396-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis | GLYCOMIMETICS, INC. (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004004636-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | GLYCOMIMETICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219158-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria | CFTR, CFB, SERPINB1 | ALDH1A1 3669/4885SLC1A3 4639/4885SLC1A2 4618/4885 |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | SELE, SELP, SELPLG | ALDH1A1 1143/4885SLC1A3 678/4885SLC1A2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.